Did Elon Musk Just Put His Skepticism Behind And Warm Up To mRNA Tech That Powers Most COVID-19 Vaccines?
Tesla CEO Elon Musk has been a skeptic of the COVID-19 vaccines and highly critical of Dr.
Nasdaq Futures Climb Solidly After Past Week’s Rout: Analyst Flags Key S&P 500 Support To Stay Above October Lows
After the market mayhem seen last week, some semblance of normalcy could return to Wall Street, thanks to the government’s move to assuage concerns in response to the banking crisis.
A Look Into Merck & Co’s Debt
Shares of Merck & Co Inc. (NYSE:MRK) decreased by 1.88% in the past three months. Before having a…
United Airlines To Rally Around 54%? Here Are 10 Other Analyst Forecasts For Friday
Piper Sandler raised the price target for Riskified Ltd. (NYSE: RSKD) from $6 to $8. Piper Sandler analyst Brent Bracelin upgraded the stock from Neutral to Overweight. Riskified shares rose 2.4% to $5.51 in pre-market trading.
Berenberg Maintains Buy on Merck & Co, Raises Price Target to $130
Berenberg analyst Luisa Hector maintains Merck & Co (NYSE:MRK) with a Buy and raises the price target from $125 to $130.
Health Care ETFs Have Lost In The Last Month – These Top Pharma Stocks Are The Reason
The Health Care Select Sector SPDR Fund (NYSE:XLV), heavily tilted towards mega-caps, lost around 5.25% over the last month, with substantial companies…
Analyst Downgrades Gossamer Bio As Merck’s Sotatercept Might Overshadow Seralutinib’s Success
Raymond James has downgraded Gossamer Bio Inc (NASDAQ:GOSS) to Market Perform from Outperform following the publication of sotatercept’s Phase 3 data in NEJM. …
Credit Suisse Maintains Outperform on Merck & Co, Raises Price Target to $126
Credit Suisse analyst Trung Huynh maintains Merck & Co (NYSE:MRK) with a Outperform and raises the price target from $125 to $126.
Atlantic Equities Maintains Overweight on Merck & Co, Raises Price Target to $127
Atlantic Equities analyst Steve Chesney maintains Merck & Co (NYSE:MRK) with a Overweight and raises the price target from $122 to $127.
After Shelving Two Keytruda Trials, Merck Touts Encouraging Data From Keytruda Regime Study In Lung Cancer Patients
Merck & Co Inc’s (NYSE:MRK) Phase 3 KEYNOTE-671 trial investigating Keytruda met one of its dual primary endpoints, event-free survival…